Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04268277
Title Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Ulm

MALT lymphoma

marginal zone B-cell lymphoma


Pembrolizumab + Rituximab

Age Groups: adult | senior
Covered Countries DEU | AUT

No variant requirements are available.